Luminar Media Group Inc., announces testing of TherOZap™ Technology against the Zika Virus and West Nile Virus

Miami, Florida, Dec. 08, 2016 (GLOBE NEWSWIRE) -- Luminar Media Group, Inc., (Luminar, OTCMKTS: LRGR), reports the TherOZap™ technology being developed by its licensing partner, The Jenex Corporation NEX:JEN.H, will undergo testing of the  novel technology against the Zika and West Nile virus. Luminar is developing a global marketing strategy based on its extensive knowledge and experience in media and marketing.  Initial efforts will focus on launching the innovative TherOZap™ device in the United States with additional markets to follow closely.

Rob Fia, CEO and Chairman Jenex comments: ""We are pleased to test our patent pending TherOZap™ technology against both the Zika and West Nile virus' especially given the wide spread of the Zika virus around the world. Jenex has engaged a world-renowned lab to initiate testing of the technology to determine if it can be effective in inactivating the virus.  We look forward to providing an update on the initial results of the tests in the near future."

Luminar CEO, Chris Cook commented; "The possibility that this research may provide an opportunity to mitigate the global risk associated with mosquito borne diseases, such as Zika, is exciting.  We are hopeful that the TherOZap™ technology will have a positive effect at reducing the harm associated with the Zika virus."

About Jenex:

Jenex is a progressive medical device technology company focused on providing consumers with quality medical devices that address their dermatological needs.  Clear and healthy skin for all is at the core of Jenex's philosophy as is the belief that such outcomes should not be a privilege for only those who can afford costly procedures and treatments.  The Company's breakthrough proprietary technology delivers effective, non-invasive and pain free skin care. The Jenex Corporation trades on the NEX JEN. For more information, visit: www.thejenexcorporation.com or www.therozap.com

About Luminar:

The Luminar Media Group has extensive knowledge and experience in the media, marketing and entertainment industries. Luminar will bring this expertise to the TherOZap™ device by developing a global marketing strategy.  Initial efforts will focus on launching the innovative TherOZap™ devicein the United States with additional markets to follow closely. Luminar was started by entrepreneurs who can identify new tools to communicate with a target audience.  At Luminar, we embrace the challenge of a constantly evolving business landscape and our determined culture will develop solutions that evolve with the changing business paradigm.

Forward-Looking Statements

This news release contains forward-looking statements about our business, or financial condition and prospects, that reflect our assumptions and beliefs based on information currently available. The Company can give no assurance that the expectations indicated by such forward-looking statements will be realized. There may be other risks and circumstances that we are unable to predict. When used in this news release, words such as "believes," "expects," "intends," "plans," "anticipates," "estimates" and similar expressions are intended to identify forward-looking statements, although there may be certain forward-looking statements not accompanied by such expressions. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including risks discussed in the company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (www.sec.gov). All forward-looking statements attributable to the Company or to persons acting on its behalf are expressly qualified in their entirety by these factors other than as required under the securities laws. The Company does not assume a duty to update these forward-looking statements.

Investors should refer to the risk factors disclosure outlined in our periodic reports filed from time-to-time with the Securities and Exchange Commission.